Predict your next investment

HEALTHCARE | Biotechnology

See what CB Insights has to offer

Founded Year




Total Raised


Date of IPO


About Novacea

Novacea is a biopharmaceutical company that had been focused on in-licensing, developing and commercializing novel cancer therapies. Novacea has two product candidates, including AsentarTM, which had been in a Phase 3 clinical trial for androgen-independent prostate cancer, and AQ4N, a hypoxia-activated prodrug. There are currently no clinical trials planned or underway for either candidate.

Novacea Headquarter Location

400 Oyster Point Boulevard Suite 200

South San Francisco, California, 94080,

United States


Latest Novacea News

Novacea (NOVC) Prices IPO at $6.50/Sh

May 16, 2016

Join SI Premium – FREE Before the open, Novacea, Inc. (Nasdaq: NOVC ) announced that it priced its initial public offering of 6,250,000 shares of its common stock at a price to the public of $6.50 per share, which was below the $11-$13 range the company had expected. All of the shares of common stock are being offered by the Company. The shares are expected to open on the Nasdaq National Market today under the symbol "NOVC. " Bear, Stearns & Co. Inc. and Cowen and Company, LLC acted as joint book-running managers with Pacific Growth Equities, LLC and HSBC Securities (USA) Inc. as co-managers. Novacea has granted to the underwriters a 30-day option to purchase up to an additional 937,500 shares at the initial public offering price to cover over-allotments, if any. Novacea, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing novel therapies for the treatment of cancer. Novacea's in-licensed product development programs include three clinical-stage oncology product candidates. The company has one product candidate, DN-101, which is in a Phase 3 clinical trial for prostate cancer and a second product candidate, vinorelbine oral, which is expected to enter into a registration trial in late 2006 for the treatment of metastatic breast cancer. Novacea's third product candidate, AQ4N, is expected to advance into a Phase 1/2 clinical trial in the second half of 2006 for the treatment of glioblastoma multiforme. You May Also Be Interested In

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.